Woman of the Week: Simcha Therapeutics’ Beatrice McQueen

From sea sponges to cytokines, the chief operating officer’s career has come full circle as she pursues a new approach to treating cancer via the immune system.

By Taren Grom • Dec. 7, 2022

10 noteworthy pharma leadership shake-ups this year

From GSK to Roche to Biogen, these were the most impactful executive changes at leading pharma companies in 2022.

By Karissa Waddick • Dec. 7, 2022

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

A historic approval could transform CSL from being ‘the biggest company no one has ever heard of’

The company’s head of R&D on its profile-raising FDA approval of a gene therapy that’s now the world’s most expensive drug. 

By Meagan Parrish • Dec. 6, 2022

Healthcare tech’s biggest busts

The metaverse, blockchain, DCTs and more — here are some of the most recent fails in healthcare tech.

By Taren Grom • Dec. 2, 2022

5 final FDA action dates to watch this year

A potential flurry of regulatory activity could be on the horizon yet this year — and several key drug approvals are at stake.

By Michael Gibney • Dec. 1, 2022

10 of our most popular articles in 2022

Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.

By Meagan Parrish • Nov. 30, 2022

Woman of the Week: Surface Oncology’s Dr. Alison O’Neill

With more than two decades of experience in oncology R&D, Dr. Alison O’Neill is helping Surface unlock the potential of next-gen immunotherapies by targeting the tumor microenvironment.

By Taren Grom • Nov. 30, 2022

One biotech’s approach to science-driven innovation

Why some in the industry say fostering creativity in drug development is all about work structures.

By Karissa Waddick • Nov. 29, 2022

Evommune’s unique method of drug discovery is more than skin deep

The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.

By Michael Gibney • Nov. 29, 2022

Avoiding a ‘bad trip’ in psychedelic clinical trials

Psychedelic drug trials pose a number of challenges, but researchers can take these steps to boost patient safety.

By Kelly Bilodeau • Nov. 28, 2022

Woman of the Week: Myriad Genetics’ Nicole Lambert

Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.

By Taren Grom • Nov. 23, 2022

How bacteria-enabled technology for wounds could also help cancer patients

Evelina Vågesjö, co-founder and CEO of the immunotherapy company Ilya Pharma, is working on a new modality to speed wound healing.

By Alexandra Pecci • Nov. 22, 2022

The next era of Greater Boston’s biotech boom

How Boston became the biotech capital of the U.S., and is now preparing for the next era of life sciences growth.  

By Karissa Waddick , Shaun Lucas , Julia Himmel • Nov. 22, 2022

In cancers with very low survival rates, Sellas aims higher

The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.

By Kelly Bilodeau • Nov. 21, 2022

Why the biopharma ‘IPO playbook’ changed in 2022

Biopharma IPOs have puttered in 2022, particularly compared to the record-breaking previous year, but they might be set to rebound.

By Michael Gibney • Nov. 21, 2022

Can a formal needs assessment simplify Speaker Bureau compliance?

In the biopharmaceutical industry, phases of innovation and change are often driven by regulatory action.

Nov. 21, 2022

Is AI just hype or a real revolution in pharma? It’s complicated

Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.

By Michael Gibney • Nov. 17, 2022

To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’

A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.

By Michael Gibney • Nov. 16, 2022

#HLTH: ‘Unicorns are real’ — and here’s how they can navigate a challenging biotech market

Venture capitalists tackle ways companies can stay afloat while the market’s turbulent waters rise.

By Meagan Parrish • Nov. 15, 2022

A ‘bold vision’ to prevent diabetes

Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

By Alexandra Pecci • Nov. 15, 2022

4 ways to bring COVID’s ‘warp speed’ to the next era of drug development

An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.

By Kelly Bilodeau • Nov. 14, 2022

Why the IRA will drive up the country’s drug bill — not lower it

On the surface, the Inflation Reduction Act is designed to lower drug prices, but its impact on innovation incentives could produce a landscape of new medicines that are costlier for patients.

By John LaMattina • Nov. 14, 2022

3 ways pharma can weather a recession

If “winter is coming” in the form of a recession, pharmas can take advantage of an inherent resiliency by crushing these three fundamentals.

By Michael Gibney • Nov. 10, 2022

Novo Nordisk’s quantum bet on ‘world changing’ computing

Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.

By Taren Grom • Nov. 10, 2022

Woman of the Week: 82VS’s Trier Bryant

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...

By Taren Grom • Nov. 9, 2022